Developer docs
API playgroundTry for free, no card

Search company profiles

Molecular Partners

Full company profile

uuid0002bso

Namestring
Molecular Partners
Legal namestring
Molecular Partners AG
Company typeenum
Public
Founded yearint
2004
Descriptiontext

Molecular Partners is a clinical-stage biopharmaceutical company headquartered in Zurich-Schlieren, Switzerland with a US office in Cambridge, Massachusetts, founded in 2004 and publicly listed on NASDAQ and SIX Swiss Exchange under ticker MOLN. The company develops a proprietary class of multi-functional protein drugs called DARPins (Designed Ankyrin Repeat Proteins), which are small (15 kDa), engineerable binding proteins supporting multi-specificity up to six targets, tunable half-life via albumin binding, and scalable bacterial fermentation manufacturing. The pipeline centers on two platform strategies: Radio-DARPins, which use DARPins as isotope-agnostic vectors for targeted alpha radiotherapeutics (lead candidates MP0712 targeting DLL3 in small cell lung cancer and MP0726 targeting mesothelin in ovarian cancer), and Switch-DARPins, which enable logic-gated conditional immune cell activation (MP0632 for solid tumors, MP0621 for stem cell transplant conditioning). Additional clinical programs include MP0317 (FAP x CD40 tumor-localized immune agonist, currently in Phase 2 for cholangiocarcinoma) and MP0533 (tetra-specific CD33/CD123/CD70/CD3 T cell engager for AML).

The company generates no commercial product revenue and operates a partnership-driven business model, monetizing the DARPin platform through upfront payments, research funding, development milestones, and royalties. Strategic alliances include a co-development partnership with Orano Med covering 10 targeted alpha therapy programs (expanded from 4 in January 2025), a February 2026 non-exclusive manufacturing agreement with Eckert & Ziegler for Actinium-225 and Lutetium-177 payloads, and historical collaborations with Novartis (COVID-19 ensovibep program and an earlier Radio-DARPin collaboration that concluded in March 2025) and AbbVie/Allergan (ophthalmology, now terminated). With approximately CHF 79 million in cash (Q1 2026) providing runway to late 2027, Molecular Partners is positioned as a platform biotech whose value inflection depends on clinical data readouts from multiple Phase 1/2a and Phase 2 oncology programs over 2026–2027.

Short descriptiontext

Molecular Partners is a clinical-stage Swiss biopharmaceutical company developing proprietary DARPin protein therapeutics for oncology, including targeted alpha radiotherapies and logic-gated immune cell engagers, monetized through co-development partnerships ahead of future commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSchlieren, Switzerland
HQ citystring
Schlieren
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
DARPin therapeutics, Targeted radiopharmaceuticals, Immune cell engagers, Clinical-stage oncology biopharmaceuticals, Multi-specific protein drugs
Industry1 code
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Oncology Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership Payments and Milestones
TypeLicensing Royalties
Description

Pre-commercial biotech receiving upfront payments, research funding, development milestones, and potential royalty streams from partnership agreements. Has received combined upfront and milestone payments of approximately CHF 450 million to date from partners including Novartis and Orano Med.

stocktitan.net
2Future Product Sales
TypeOne Time License
Description

Pre-revenue company anticipating commercializing drug candidates following regulatory approvals. Multiple programs in clinical development (MP0712, MP0317, MP0533) targeting oncology indications with significant unmet need.

stocktitan.net
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Molecular Partners is a clinical-stage biopharmaceutical company that develops DARPin (Designed Ankyrin Repeat Protein) therapeutics — a proprietary class of multi-functional protein drugs — for the treatment of cancer. Its portfolio is built on two platform technologies: Radio-DARPin therapeutics (targeted alpha radiotherapeutics using isotope-agnostic vectors such as 212Pb) and Switch-DARPin logic-gated immune cell engagers, with clinical candidates targeting small cell lung cancer, AML, cholangiocarcinoma, and ovarian cancer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 data published in Nature Cancer: tumor-localized CD40 activation with favorable safety profile in 46 patients with advanced solid tumors, 1 unconfirmed partial response, 14 cases of stable disease
+2 more records
Product overview1 text field

Molecular Partners is a clinical-stage biotech company pioneering DARPin (Designed Ankyrin Repeat Protein) therapeutics, a novel class of multi-functional protein drugs. The company's portfolio centers on two technology platforms: Radio-DARPin therapy (targeted alpha radiotherapeutics using isotope-agnostic DARPin vectors) and Switch-DARPin (logic-gated immune cell engagers for conditional activation). The clinical pipeline includes MP0712 (Phase 1/2a, DLL3-targeting Radio-DARPin for small cell lung cancer, co-developed with Orano Med), MP0317 (Phase 2, FAP x CD40 for cholangiocarcinoma and solid tumors), and MP0533 (Phase 1/2a, tetra-specific T cell engager for AML). The preclinical and research-stage portfolio includes MP0726 (Radio-DARPin for ovarian cancer), MP0632 (Switch-DARPin T cell engager for solid tumors), and MP0621 (Switch-DARPin for stem cell transplantation conditioning). Four additional undisclosed Radio-DARPin programs are in research. The company operates from Switzerland (Zurich-Schlieren headquarters) and Massachusetts (Cambridge, MA office).

Product and service6 records
1MP0712
CategoryClinical candidate (Phase 1/2a)
Description

A targeted alpha radiotherapy (Radio-DARPin) directed against DLL3 for the treatment of small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancers. Delivers the potent alpha-emitting therapeutic isotope 212Pb to DLL3-expressing tumor cells. Co-developed with Orano Med.

2MP0726
CategoryClinical candidate
Description

A radiopharmaceutical delivering the potent alpha-emitting therapeutic isotope 212Pb to mesothelin (MSLN)-expressing tumors, particularly ovarian cancer (>80% prevalence), designed to selectively bind to an MSLN region proximal to the target cell membrane to avoid impact from shedding. Co-developed with Orano Med.

3MP0317
CategoryClinical candidate (Phase 2)
Description

A tumor-localized CD40 agonist (FAP x CD40) designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP) at high density in tumor stroma. Currently in Phase 2 for cholangiocarcinoma in combination with durvalumab plus gemcitabine-cisplatin.

4MP0533
CategoryClinical candidate (Phase 1/2a)
Description

A tetra-specific T cell engager targeting CD33 x CD123 x CD70 x CD3 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS/AML). Designed to kill AML cells including leukemic stem cells while minimizing damage to healthy cells, with binding strength increasing based on number of targets engaged.

5MP0632
CategoryResearch / Preclinical candidate
Description

A logic-gated Switch-DARPin T cell engager targeting MSLN and EpCAM for ovarian cancer and other solid tumors. The CD3-engaging DARPin is conditionally activated only upon binding to both MSLN and EpCAM, enabling conditional tumor-localized immune activation, with half-life extended through an Fc domain.

6MP0621
CategoryPreclinical candidate
Description

A Switch-DARPin candidate designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation. Combines cKit targeting with conditional blockade of CD47 'do-not-eat-me' signal on HSCs via a Switch-DARPin mechanism.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-26
Description

Non-exclusive development agreement for manufacturing Radio-DARPin therapeutics using Actinium-225 and Lutetium-177 payloads. Eckert & Ziegler provides services from its facilities including newly established Alpha Laboratory in Berlin, Germany dedicated to alpha emitters. Supports expansion of radiopharmaceutical capabilities beyond existing Orano Med partnership.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Co-development agreement for Radio-DARPin Therapies using 212Pb targeted alpha therapy technology. Initially 4 programs (DLL3/MP0712 and MSLN/MP0726), expanded in January 2025 to include 6 additional programs for total of 10 potential programs. Orano Med holds option to co-develop 2 of the 6 additional programs on 50/50 basis with commercialization rights. Molecular Partners leads development of additional programs with royalty arrangements. Shared costs for preclinical and clinical development.

Strategic tierLegacyTypeStrategic or Co-development PartnerAnnounced on2020-10-01
Description

October 2020 collaboration for DARPin candidates for COVID-19; Novartis in-licensed ensovibep (MP0420) in January 2022 receiving CHF 150 million milestone. EUA withdrawn January 2023; rights returned to Molecular Partners in January 2024. December 2021 research and collaboration agreement for Radio-DARPin Therapies concluded March 2025 with $20 million upfront payment received.

Strategic tierLegacyTypeStrategic or Co-development PartnerAnnounced on2011-01-01
Description

Discovery alliance in ophthalmology through AbbVie's Allergan subsidiary. Key candidate abicipar developed through registrational phase for nAMD and DME. Program provided clinical, drug design and manufacturing learnings. Discovery alliance now terminated.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Bicycle Therapeutics develops bicyclic peptide drug conjugates and T cell engagers (BT8009, BT7480), a novel constrained-peptide platform analogous to Molecular Partners' DARPin scaffold; both target oncology with multi-specific engineered protein constructs and pursue similar tumor-localized activation strategies.

TypeBroad incumbent
Description

Novartis is the commercial leader in radioligand therapy with Pluvicto (lutetium-177 PSMA-617) and was Molecular Partners' prior Radio-DARPin partner until March 2025; it represents both a competitive benchmark and a potential future acquirer/large-pharma partner for the Radio-DARPin pipeline.

TypeDirect peer
Description

Telix is a commercial-stage radiopharmaceutical company developing diagnostic and therapeutic agents (Illuccix, PSMA-617 generics pipeline) targeting oncology indications including prostate, kidney, and brain cancers, directly competing in the same modality space as Molecular Partners' Radio-DARPin program.

TypeBroad incumbent
Description

Lantheus is a specialty radiopharmaceutical company with established diagnostic imaging agents (PNT2002, Pylarify) and an emerging therapeutic pipeline; its scale and commercial radiopharma infrastructure make it a direct comparable for valuation purposes and a potential strategic acquirer.

TypeDirect peer
Description

MacroGenics develops multi-specific DART and TRIDENT molecules for oncology, including T cell engagers and antibody-recruiting therapeutics; it is a clinical-stage oncology peer with comparable bispecific/multi-specific protein engineering expertise targeting similar hematologic and solid tumor indications.

TypeBroad incumbent
Description

Bayer markets Xofigo (radium-223) and acquired Noria Therapeutics and Algeta, positioning it as a strategic radiopharma incumbent; its deep oncology commercial infrastructure and target alpha therapy expertise make it comparable to Molecular Partners' Orano Med-backed Radio-DARPin approach.

TypeDirect peer
Description

Harpoon developed tri-specific T cell engagers (HPN328, HPN217) using a ProTriTAC platform with conditional T cell activation conceptually similar to Molecular Partners' Switch-DARPin mechanism; it was acquired by Merck in 2024, providing a recent valuation reference point for clinical-stage multi-specific T cell engager platforms.

TypeEmerging player
Description

Pyxis Oncology is a clinical-stage oncology biotech developing antibody-drug conjugates and immuno-oncology therapeutics including tumor-localized immune activation approaches (microtubule-inhibitor ADCs and immune engager candidates), positioning it as a peer in next-generation oncology biologics with similar early-stage clinical risk profile.

TypeEmerging player
Description

Cullinan Oncology is a clinical-stage oncology company developing multiple assets across modalities including T cell engagers, ADCs, and immune modulators; its diversified early-stage oncology pipeline and similar headcount/revenue scale make it a direct comparable for pipeline breadth and capital efficiency benchmarking.

TypeBroad incumbent
Description

Genmab is a commercial-stage biotechnology company specializing in bispecific antibody platforms (Duobody, Hexabody) with approved products including Rybrevant and Tecvayli, providing a profitable, scaled analog for evaluating multi-specific antibody-derived therapeutic platforms targeting oncology indications similar to Molecular Partners' pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Molecular Partners

Oncology Biopharmaceuticalsmolecularpartners.com

Molecular Partners is a clinical-stage Swiss biopharmaceutical company developing proprietary DARPin protein therapeutics for oncology, including targeted alpha radiotherapies and logic-gated immune cell engagers, monetized through co-development partnerships ahead of future commercialization.

What Molecular Partners does

Molecular Partners is a clinical-stage biopharmaceutical company headquartered in Zurich-Schlieren, Switzerland with a US office in Cambridge, Massachusetts, founded in 2004 and publicly listed on NASDAQ and SIX Swiss Exchange under ticker MOLN. The company develops a proprietary class of multi-functional protein drugs called DARPins (Designed Ankyrin Repeat Proteins), which are small (15 kDa), engineerable binding proteins supporting multi-specificity up to six targets, tunable half-life via albumin binding, and scalable bacterial fermentation manufacturing. The pipeline centers on two platform strategies: Radio-DARPins, which use DARPins as isotope-agnostic vectors for targeted alpha radiotherapeutics (lead candidates MP0712 targeting DLL3 in small cell lung cancer and MP0726 targeting mesothelin in ovarian cancer), and Switch-DARPins, which enable logic-gated conditional immune cell activation (MP0632 for solid tumors, MP0621 for stem cell transplant conditioning). Additional clinical programs include MP0317 (FAP x CD40 tumor-localized immune agonist, currently in Phase 2 for cholangiocarcinoma) and MP0533 (tetra-specific CD33/CD123/CD70/CD3 T cell engager for AML).

The company generates no commercial product revenue and operates a partnership-driven business model, monetizing the DARPin platform through upfront payments, research funding, development milestones, and royalties. Strategic alliances include a co-development partnership with Orano Med covering 10 targeted alpha therapy programs (expanded from 4 in January 2025), a February 2026 non-exclusive manufacturing agreement with Eckert & Ziegler for Actinium-225 and Lutetium-177 payloads, and historical collaborations with Novartis (COVID-19 ensovibep program and an earlier Radio-DARPin collaboration that concluded in March 2025) and AbbVie/Allergan (ophthalmology, now terminated). With approximately CHF 79 million in cash (Q1 2026) providing runway to late 2027, Molecular Partners is positioned as a platform biotech whose value inflection depends on clinical data readouts from multiple Phase 1/2a and Phase 2 oncology programs over 2026–2027.

Molecular Partners firmographics

Firmographics
Name
Molecular Partners
Legal name
Molecular Partners AG
Website
https://molecularpartners.com
Company type
Public
Founded year
2004
Operating status
Operating
Headcount range
1–10 employees
Short description
Molecular Partners is a clinical-stage Swiss biopharmaceutical company developing proprietary DARPin protein therapeutics for oncology, including targeted alpha radiotherapies and logic-gated immune cell engagers, monetized through co-development partnerships ahead of future commercialization.
Ownership category
akta.pro rank

Molecular Partners industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • DARPin therapeutics
  • Targeted radiopharmaceuticals
  • Immune cell engagers
  • Clinical-stage oncology biopharmaceuticals
  • Multi-specific protein drugs

Where Molecular Partners is headquartered

Location

Headquarters

HQ city
Schlieren
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Molecular Partners business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Partnership Payments and Milestones: Pre-commercial biotech receiving upfront payments, research funding, development milestones, and potential royalty streams from partnership agreements. Has received combined upfront and milestone payments of approximately CHF 450 million to date from partners including Novartis and Orano Med.
  2. Future Product Sales: Pre-revenue company anticipating commercializing drug candidates following regulatory approvals. Multiple programs in clinical development (MP0712, MP0317, MP0533) targeting oncology indications with significant unmet need.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Molecular Partners product offering

Product offering

Core offering

Molecular Partners is a clinical-stage biopharmaceutical company that develops DARPin (Designed Ankyrin Repeat Protein) therapeutics — a proprietary class of multi-functional protein drugs — for the treatment of cancer. Its portfolio is built on two platform technologies: Radio-DARPin therapeutics (targeted alpha radiotherapeutics using isotope-agnostic vectors such as 212Pb) and Switch-DARPin logic-gated immune cell engagers, with clinical candidates targeting small cell lung cancer, AML, cholangiocarcinoma, and ovarian cancer.

Product overview

Molecular Partners is a clinical-stage biotech company pioneering DARPin (Designed Ankyrin Repeat Protein) therapeutics, a novel class of multi-functional protein drugs. The company's portfolio centers on two technology platforms: Radio-DARPin therapy (targeted alpha radiotherapeutics using isotope-agnostic DARPin vectors) and Switch-DARPin (logic-gated immune cell engagers for conditional activation). The clinical pipeline includes MP0712 (Phase 1/2a, DLL3-targeting Radio-DARPin for small cell lung cancer, co-developed with Orano Med), MP0317 (Phase 2, FAP x CD40 for cholangiocarcinoma and solid tumors), and MP0533 (Phase 1/2a, tetra-specific T cell engager for AML). The preclinical and research-stage portfolio includes MP0726 (Radio-DARPin for ovarian cancer), MP0632 (Switch-DARPin T cell engager for solid tumors), and MP0621 (Switch-DARPin for stem cell transplantation conditioning). Four additional undisclosed Radio-DARPin programs are in research. The company operates from Switzerland (Zurich-Schlieren headquarters) and Massachusetts (Cambridge, MA office).

Differentiator

Problem solved

Functional benefit

Products and services

  • MP0712 A targeted alpha radiotherapy (Radio-DARPin) directed against DLL3 for the treatment of small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancers. Delivers the potent alpha-emitting therapeutic isotope 212Pb to DLL3-expressing tumor cells. Co-developed with Orano Med.
  • MP0726 A radiopharmaceutical delivering the potent alpha-emitting therapeutic isotope 212Pb to mesothelin (MSLN)-expressing tumors, particularly ovarian cancer (>80% prevalence), designed to selectively bind to an MSLN region proximal to the target cell membrane to avoid impact from shedding. Co-developed with Orano Med.
  • MP0317 A tumor-localized CD40 agonist (FAP x CD40) designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP) at high density in tumor stroma. Currently in Phase 2 for cholangiocarcinoma in combination with durvalumab plus gemcitabine-cisplatin.
  • MP0533 A tetra-specific T cell engager targeting CD33 x CD123 x CD70 x CD3 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS/AML). Designed to kill AML cells including leukemic stem cells while minimizing damage to healthy cells, with binding strength increasing based on number of targets engaged.
  • MP0632 A logic-gated Switch-DARPin T cell engager targeting MSLN and EpCAM for ovarian cancer and other solid tumors. The CD3-engaging DARPin is conditionally activated only upon binding to both MSLN and EpCAM, enabling conditional tumor-localized immune activation, with half-life extended through an Fc domain.
  • MP0621 A Switch-DARPin candidate designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation. Combines cKit targeting with conditional blockade of CD47 'do-not-eat-me' signal on HSCs via a Switch-DARPin mechanism.

Quantifiable outcome

  • Phase 1 data published in Nature Cancer: tumor-localized CD40 activation with favorable safety profile in 46 patients with advanced solid tumors, 1 unconfirmed partial response, 14 cases of stable disease
  • +2 more outcomes

Companies that use Molecular Partners

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Molecular Partners technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Molecular Partners partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and legacy.

  • Eckert & ZieglercoreTechnology or Integration · 26 February 2026Non-exclusive development agreement for manufacturing Radio-DARPin therapeutics using Actinium-225 and Lutetium-177 payloads. Eckert & Ziegler provides services from its facilities including newly established Alpha Laboratory in Berlin, Germany dedicated to alpha emitters. Supports expansion of radiopharmaceutical capabilities beyond existing Orano Med partnership.
  • Orano MedcoreStrategic or Co-development Partner · 1 January 2024Co-development agreement for Radio-DARPin Therapies using 212Pb targeted alpha therapy technology. Initially 4 programs (DLL3/MP0712 and MSLN/MP0726), expanded in January 2025 to include 6 additional programs for total of 10 potential programs. Orano Med holds option to co-develop 2 of the 6 additional programs on 50/50 basis with commercialization rights. Molecular Partners leads development of additional programs with royalty arrangements. Shared costs for preclinical and clinical development.
  • NovartislegacyStrategic or Co-development Partner · 1 October 2020October 2020 collaboration for DARPin candidates for COVID-19; Novartis in-licensed ensovibep (MP0420) in January 2022 receiving CHF 150 million milestone. EUA withdrawn January 2023; rights returned to Molecular Partners in January 2024. December 2021 research and collaboration agreement for Radio-DARPin Therapies concluded March 2025 with $20 million upfront payment received.
  • AbbVie (Allergan)legacyStrategic or Co-development Partner · 1 January 2011Discovery alliance in ophthalmology through AbbVie's Allergan subsidiary. Key candidate abicipar developed through registrational phase for nAMD and DME. Program provided clinical, drug design and manufacturing learnings. Discovery alliance now terminated.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Molecular Partners competitors and assessment

Company assessment

Direct peers

  • Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide drug conjugates and T cell engagers (BT8009, BT7480), a novel constrained-peptide platform analogous to Molecular Partners' DARPin scaffold; both target oncology with multi-specific engineered protein constructs and pursue similar tumor-localized activation strategies.
  • Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company developing diagnostic and therapeutic agents (Illuccix, PSMA-617 generics pipeline) targeting oncology indications including prostate, kidney, and brain cancers, directly competing in the same modality space as Molecular Partners' Radio-DARPin program.
  • MacroGenics: MacroGenics develops multi-specific DART and TRIDENT molecules for oncology, including T cell engagers and antibody-recruiting therapeutics; it is a clinical-stage oncology peer with comparable bispecific/multi-specific protein engineering expertise targeting similar hematologic and solid tumor indications.
  • Harpoon Therapeutics: Harpoon developed tri-specific T cell engagers (HPN328, HPN217) using a ProTriTAC platform with conditional T cell activation conceptually similar to Molecular Partners' Switch-DARPin mechanism; it was acquired by Merck in 2024, providing a recent valuation reference point for clinical-stage multi-specific T cell engager platforms.

Broad incumbents

  • Novartis (Pluvicto / Radioligand Therapy): Novartis is the commercial leader in radioligand therapy with Pluvicto (lutetium-177 PSMA-617) and was Molecular Partners' prior Radio-DARPin partner until March 2025; it represents both a competitive benchmark and a potential future acquirer/large-pharma partner for the Radio-DARPin pipeline.
  • Lantheus Holdings: Lantheus is a specialty radiopharmaceutical company with established diagnostic imaging agents (PNT2002, Pylarify) and an emerging therapeutic pipeline; its scale and commercial radiopharma infrastructure make it a direct comparable for valuation purposes and a potential strategic acquirer.
  • Bayer (Radiopharmaceuticals / Xofigo): Bayer markets Xofigo (radium-223) and acquired Noria Therapeutics and Algeta, positioning it as a strategic radiopharma incumbent; its deep oncology commercial infrastructure and target alpha therapy expertise make it comparable to Molecular Partners' Orano Med-backed Radio-DARPin approach.
  • Genmab: Genmab is a commercial-stage biotechnology company specializing in bispecific antibody platforms (Duobody, Hexabody) with approved products including Rybrevant and Tecvayli, providing a profitable, scaled analog for evaluating multi-specific antibody-derived therapeutic platforms targeting oncology indications similar to Molecular Partners' pipeline.

Emerging players

  • Pyxis Oncology: Pyxis Oncology is a clinical-stage oncology biotech developing antibody-drug conjugates and immuno-oncology therapeutics including tumor-localized immune activation approaches (microtubule-inhibitor ADCs and immune engager candidates), positioning it as a peer in next-generation oncology biologics with similar early-stage clinical risk profile.
  • Cullinan Oncology: Cullinan Oncology is a clinical-stage oncology company developing multiple assets across modalities including T cell engagers, ADCs, and immune modulators; its diversified early-stage oncology pipeline and similar headcount/revenue scale make it a direct comparable for pipeline breadth and capital efficiency benchmarking.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Molecular Partners social profiles

Digital presence

Molecular Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Molecular Partners leadership team

Management profile

Number of profiles

Profiles11 records

Molecular Partners subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Molecular Partners funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Molecular Partners M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecular Partners

What does Molecular Partners do?

Molecular Partners is a clinical-stage biopharmaceutical company that develops DARPin (Designed Ankyrin Repeat Protein) therapeutics — a proprietary class of multi-functional protein drugs — for the treatment of cancer. Its portfolio is built on two platform technologies: Radio-DARPin therapeutics (targeted alpha radiotherapeutics using isotope-agnostic vectors such as 212Pb) and Switch-DARPin logic-gated immune cell engagers, with clinical candidates targeting small cell lung cancer, AML, cholangiocarcinoma, and ovarian cancer.

Is Molecular Partners a public or private company?

Molecular Partners is a public company. It is classified as public and is currently operating.

When was Molecular Partners founded?

Molecular Partners was founded in 2004. It employs 1 to 10 people.

Where is Molecular Partners based?

Molecular Partners is headquartered in Schlieren, Switzerland, in the Europe region.

How does Molecular Partners make money?

Two revenue lines are on record. Partnership Payments and Milestones are the primary driver. The others are future Product Sales.

Who are Molecular Partners's main competitors?

Direct peers on record are Bicycle Therapeutics, Telix Pharmaceuticals, MacroGenics and Harpoon Therapeutics. Broad incumbents are Novartis (Pluvicto / Radioligand Therapy), Lantheus Holdings, Bayer (Radiopharmaceuticals / Xofigo) and Genmab. Emerging players are Pyxis Oncology and Cullinan Oncology.

Does Molecular Partners have an API?

No public API is recorded for Molecular Partners.

What industry is Molecular Partners in?

Molecular Partners's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialMolecular Partners To Present At Inaugural UBS Global Biopharma ConferenceMolecular Partners CEO Patrick Amstutz will present at the inaugural UBS Global Biopharma Conference on November 17 in London. The company's lead medicine MP0712, targeting DLL3 with 212Pb, is advancing in a US Phase 1/2a study for small cell lung cancer and other neuroendocrine cancers.GlobeNewswireMolecular Partners to Present at Inaugural UBS Global Biopharma ConferenceMolecular Partners AG will present its latest developments and outlook at the Inaugural UBS Biopharma Conference in London on November 16-17, 2026. CEO Patrick Amstutz will speak on November 17, with a webcast available on the company's website.FinancialContent Business PageMolecular Partners to Present at Inaugural UBS Global Biopharma ConferenceMolecular Partners AG will present its latest developments and outlook at the Inaugural UBS Biopharma Conference in London on November 16-17, 2026. CEO Patrick Amstutz will speak on November 17, with a webcast available on the company's website.Stock TitanMolecular Partners to Present at UBS Biopharma ConferenceMolecular Partners AG will present its latest developments and outlook at the inaugural UBS Biopharma Conference in London on November 16-17, 2026. CEO Patrick Amstutz will speak on Tuesday, November 17, with a webcast available on the company's website.Defense WorldContrasting Molecular Partners (MOLN) and Its PeersMolecular Partners is compared to biotechnology peers on ratings, profitability, and valuation. It has a consensus target price of $8.38, implying 170.16% upside, while competitors beat it on 8 of 13 factors. The company trades at a higher P/E ratio and has lower institutional ownership.American Banking and Market NewsHead-To-Head Contrast: Molecular Partners (NASDAQ:MOLN) and Cartesian Therapeutics (NASDAQ:RNAC)Cartesian Therapeutics beats Molecular Partners on 9 of 14 factors, including analyst ratings and upside potential. Cartesian has a stronger consensus rating and higher probable upside, while Molecular Partners has higher revenue and a lower price-to-earnings ratio.Business & FinancialMolecular Partners Presents New Preclinical Data For Next-Generation T Cell Engager MP0632 At SITC 2026Molecular Partners presented new preclinical data for MP0632, a logic-gated T cell engager, at SITC 2026. The data show potent tumor killing with no impact on healthy tissues expressing MSLN or EpCAM, supporting IND-enabling studies for solid tumors co-expressing both antigens.FinancialContent Business PageMolecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026Molecular Partners presented new preclinical data for MP0632, a logic-gated T cell engager, at SITC 2026. The data show potent tumor killing with no impact on healthy tissues expressing MSLN or EpCAM, supporting IND-enabling studies in solid tumors co-expressing both antigens.GlobeNewswireMolecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026Molecular Partners presented new preclinical data for MP0632, a logic-gated T cell engager, at SITC 2026. The data show potent tumor killing with no impact on healthy tissues expressing MSLN or EpCAM, supporting IND-enabling studies for solid tumors co-expressing both antigens.Stock TitanMolecular Partners MP0632 data show preclinical safetyMolecular Partners presented new preclinical data for its T cell engager MP0632 at SITC 2026, showing no detectable impact on primary human mesothelial or epithelial cells. The data support advancing MP0632 into IND-enabling studies for solid tumors co-expressing MSLN and EpCAM, such as ovarian, endometrial, lung, and pancreatic cancers.